Free Trial
NASDAQ:SANA

Sana Biotechnology Q4 2025 Earnings Report

Sana Biotechnology logo
$3.62 +0.14 (+3.87%)
As of 11:48 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Sana Biotechnology EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Sana Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sana Biotechnology Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 3, 2026
Conference Call Time
3:00PM ET

Upcoming Earnings

Sana Biotechnology's Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sana Biotechnology Earnings Headlines

Trump and Elon are BACK
15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IPOs", a new Elon Musk innovation is quietly being rolled out nationwide. It's been 27 years in the making, and it could have a radical impact on how millions of people manage their money… and even collect Social Security.tc pixel
See More Sana Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sana Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sana Biotechnology and other key companies, straight to your email.

About Sana Biotechnology

Sana Biotechnology (NASDAQ:SANA) is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9. Sana’s ex vivo pipeline includes allogeneic cell programs designed to target hematologic malignancies and solid tumors, while its in vivo portfolio focuses on directly delivering therapeutic genes to tissues for the treatment of hereditary diseases. Preclinical research efforts span multiple therapeutic areas, with a view to advancing candidates into human trials.

Founded in 2018 as an independent enterprise originating from the life-science incubator Flagship Pioneering, Sana Biotechnology is headquartered in Seattle, Washington, with research and development facilities in Cambridge, Massachusetts. Its global operations support collaborative partnerships and research alliances aimed at accelerating the translation of cell therapies from the laboratory to the clinic.

Under the leadership of Chief Executive Officer Steve Harr, Sana has assembled a multidisciplinary management team with expertise in biotechnology, immunology and drug development. The company continues to expand its scientific and manufacturing capabilities while advancing a pipeline intended to address unmet medical needs and improve long-term patient outcomes.

View Sana Biotechnology Profile